NCT00002349已完成不适用
A Pilot Study to Compare the Antiviral and Immunologic Effects of Stavudine ( d4T ) Versus Placebo in Subjects With Evidence of Recent HIV Infection.
Bristol-Myers Squibb6 个研究点 分布在 1 个国家目标入组 40 人开始时间: 1995年1月最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 40
- 试验地点
- 6
研究概览
简要总结
To compare the antiviral effect of stavudine ( d4T ) versus placebo in patients with evidence of recent HIV infection.
Also, to compare the immunologic effects and effects on quality of life of d4T in these patients.
详细描述
Patients receive d4T or placebo every 12 hours for 4 weeks, after which dose decreases (or placebo) every 12 hours. Treatment continues for at least 48 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (6)
Loading locations...
相似试验
已完成
2 期
The Effectiveness of Three Drug Combinations in HIV-Infected Patients Who Have Taken Zidovudine for More Than 12 WeeksHIV InfectionsNCT00001063National Institute of Allergy and Infectious Diseases (NIAID)200
已完成
3 期
A Study to Evaluate the Use of Stavudine (d4T) to Treat AIDS Dementia ComplexAIDS Dementia ComplexHIV InfectionsNCT00002246Bristol-Myers Squibb20
已完成
3 期
Effectiveness and Safety of Two Forms of Stavudine in HIV-Infected PatientsHIV InfectionsNCT00005918Bristol-Myers Squibb730
已完成
2 期
A Study of Viracept in HIV-Positive WomenHIV InfectionsNCT00002171Agouron Pharmaceuticals
已完成
3 期
Dose Optimisation of Stavudine for the Treatment of HIV InfectionAcquired Immune Deficiency SyndromeHuman Immunodeficiency VirusNCT02670772Willem Daniel Francois Venter1,077